Goldman Sachs
ANEB

Goldman Sachs’s Anebulo Pharmaceuticals ANEB Stock Holding History

Goldman Sachs’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,600
Closed -$16.7K – 6315
2025
Q2 		$16.7K Sell
11,600
-36,354
-76% -$41.5K ﹤0.01% 5994
2025
Q1 		$62.3K Buy
+47,954
New +$70.5K ﹤0.01% 5858

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs's ANEB Position: Q3 2025 in Review

Goldman Sachs sold out of Anebulo Pharmaceuticals (ANEB) in Q3 2025, closing a stake of 11,600 shares — an estimated $16.7K sold.

Goldman Sachs first reported a position in ANEB in Q1 2025 and held it in 2 quarters. The position peaked at $62.3K in Q1 2025. 21 funds tracked by Wall St. Rank hold ANEB as of Q3 2025.

  • Goldman Sachs reported no remaining Anebulo Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 11,600 Anebulo Pharmaceuticals shares in Q3 2025, an estimated $16.7K.
  • Goldman Sachs first reported a position in Anebulo Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Goldman Sachs's Anebulo Pharmaceuticals position peaked at $62.3K in Q1 2025.
  • 21 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.